Off the wire
• South African stocks close lower as financials lead losses  • Smoke-free Nepal possible only through clean cooking program: report  • U.S. stocks turn lower amid GDP data  • French household sentiment indicator hits 10-year high: Insee  • Ireland should not rule out joining Britain in quitting EU: former diplomat  • Kenya Red Cross appeals 10 mln USD for drought response  • Roundup: Nadal to meet Federer in Australian Open final  • News Analysis: UK-US ties under Trump may become "more of an illusion"  • Kenya's bourse turnover doubles on increased foreign inflows  • African leaders urged to tackle illicit financial flows  
You are here: 　 Home

EMA says dienogest/ethinylestradiol used for acne

Xinhua, January 28, 2017 Adjust font size:

The European Medicines Agency (EMA) said on Friday that medicines containing a combination of dienogest 2 mg and ethinylestradiol 0.03 mg can continue to be used to treat moderate acne when suitable treatments applied to the skin or antibiotics taken by mouth have not worked.

EMA's Committee for Medicinal Products for Human Use (CHMP) evaluated the existing data on the effectiveness of the combination in the treatment of acne and found that there was sufficient evidence to support its use in moderate acne.

However, EMA said in its press release that these medicines should only be used in women who choose oral contraception.

The review of medicines containing dienogest 2 mg and ethinylestradiol 0.03 mg for acne was initiated on February 25, 2016 at the request of British medicines agency.

According to the release, the CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all European Union member states. Endit